Potential new MRSA-killing antibiotic developed by mining microbial 'dark matter'

8 January 2015
bacteria-big

Researchers at Northeastern University in Boston, Massachusetts, USA, have made a breakthrough in antibiotic research.

A novel approach for growing bacteria in soil has produced 25 new antibiotics, and one has been branded “very promising.” Although soil is rich in microbes, only 1% of those can be successfully grown in a laboratory. By creating a device, the iChip, that works under the surface of the soil, researchers were able to determine that they can grow nearly half of all soil bacteria.

Kim Lewis, the lead scientist in the research and co-founder of NovoBiotic Pharmaceuticals, said: "So far 25 new antibiotics have been discovered using this method and teixobactin is the latest and most promising one. [The study shows] uncultured bacteria do harbor novel chemistry that we have not seen before. That is a promising source of new antimicrobials and will hopefully help revive the field of antibiotic discovery."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical